The Akt-mTOR pathway in Down's syndrome: The potential use of Rapamycin/rapalogs for treating cognitive deficits

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 1, 2014, Pages 34-40

  Troca Marín, José Antonio ^a   Casañas, Juan José ^a   Benito, Itziar ^a,b   Montesinos, María Luz ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Akt; Brain derived neurotrophic factor; Down's syndrome; Local translation; Mammalian target of rapamycin; Rapamycin; Trisomy 21; Ts1Cje

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; N METHYL DEXTRO ASPARTIC ACID; NEUROTROPHIN; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; ZOTAROLIMUS;

5' UNTRANSLATED REGION; ACTIN FILAMENT; ARTICLE; CHEMICAL STRUCTURE; CHROMOSOME 21; COGNITIVE DEFECT; DOWN SYNDROME; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; KIDNEY CARCINOMA; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84896718198     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660184     Document Type: Article

References (87)

1. Dazert E, Hall MN. Mtor signaling in disease. Curr Opin Cell Biol 2011; 23(6): 744-55.
2. Troca-Marin JA, Alves-Sampaio A, Montesinos ML. Deregulated mTOR-mediated translation in intellectual disability. Prog Neurobiol 2012; 96(2): 268-82.
3. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008; 27(Suppl 2): S43-S51.
4. Troca-Marin JA, Alves-Sampaio A, Montesinos ML. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. J Neurosci 2011; 31(26): 9445-9455.
5. Hoeffer CA, Klann E. Mtor signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010; 33(2): 67-75.
6. Lee CC, Huang CC, Hsu KS. Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 2011; 61(4): 867-879.
7. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR): mediates TOR action. Cell 2002; 110(2): 177-189.
8. Kim DH, Sarbassov DD, Ali SM, et al. Mtor interacts with raptor to form a nutrient-sensitive complex that signals To the cell growth machinery. Cell 2002; 110(2): 163-175.
9. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6(11): 1122-1128.
10. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14(14): 1296-1302.
11. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003; 278(18): 15461-15464.
12. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 2000; 267(21): 6321-6330.
13. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol 2005; 169(2): 245-256.
14. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22(2): 159-168.
15. Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008; 27(14): 1932-1943.
16. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005; 25(49): 11288-11299.
17. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005; 25(49): 11300-11312.
18. Jossin Y, Goffinet AM. Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol Cell Biol 2007; 27(20): 7113-7124.
19. Chow DK, Groszer M, Pribadi M, et al. Laminar and compartmental regulation of dendritic growth in mature cortex. Nat Neurosci 2009; 12(2): 116-118.
20. Tang SJ, Reis G, Kang H, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99(1): 467-472.
21. Cammalleri M, Lutjens R, Berton F, et al. Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc Natl Acad Sci USA 2003; 100(24): 14368-14373.
22. Hou L, Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 2004; 24(28): 6352-6361.
23. Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci 2006; 26(50): 12977-12983.
24. Stoica L, Zhu PJ, Huang W, et al. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci USA 2011; 108(9): 3791-3796.
25. Tsokas P, Grace EA, Chan P, et al. Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. J Neurosci 2005; 25(24): 5833-5843.
26. Vickers CA, Dickson KS, Wyllie DJ. Induction and maintenance of late-phase long-term potentiation in isolated dendrites of rat hippocampal CA1 pyramidal neurones. J Physiol 2005; 568(Pt 3): 803-813.
27. Gong R, Park CS, Abbassi NR, Tang SJ. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem 2006; 281(27): 18802-18815.
28. Bekinschtein P, Katche C, Slipczuk LN, et al. Mtor signaling in the hippocampus is necessary for memory formation. Neurobiol Learn Mem 2007; 87(2): 303-307.
29. Slipczuk L, Bekinschtein P, Katche C, et al. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS One 2009; 4(6): e6007.
30. Jobim PF, Pedroso TR, Christoff RR, et al. Inhibition of mTOR by rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory. Neurobiol Learn Mem 2012; 97(1): 105-112.
31. Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 2000; 288(5469): 1254-1257.
32. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30(2): 694-702.
33. Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010; 30(32): 10624-10638.
34. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008; 14(8): 843-848.
35. Ricciardi S, Boggio EM, Grosso S, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 2011; 20(6): 1182-1196.
36. Sago H, Carlson EJ, Smith DJ, et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95(11): 6256-6261.
37. Delabar JM, Theophile D, Rahmani Z, et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993; 1(2): 114-124.
38. Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA 1994; 91(11): 4997-5001.
39. Belichenko NP, Belichenko PV, Kleschevnikov AM, et al. The Down syndrome critical region is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 2009; 29(18): 5938-5948.
40. Contestabile A, Benfenati F, Gasparini L. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog Neurobiol 2010; 91(1): 1-22.
41. Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol 2007; 504(4): 329-345.
42. Siarey RJ, Villar AJ, Epstein CJ, Galdzicki Z. Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 2005; 49(1): 122-128.
43. Sago H, Carlson EJ, Smith DJ, et al. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr Res 2000; 48(5): 606-613.
44. Olson LE, Roper RJ, Baxter LL, et al. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev Dyn 2004; 230(3): 581-589.
45. Moldrich RX, Dauphinot L, Laffaire J, et al. Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. J Neurosci Res 2009; 87(14): 3143-3152.
46. Hewitt CA, Ling KH, Merson TD, et al. Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One 2010; 5(7): e11561.
47. Ishihara K, Amano K, Takaki E, et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex 2010; 20(5): 1131-1143.
48. Richtsmeier JT, Zumwalt A, Carlson EJ, Epstein CJ, Reeves RH. Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. Am J Med Genet, 2002; 107(4): 317-324.
49. Takei N, Inamura N, Kawamura M, et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci 2004; 24(44): 9760-9769.
50. Tanaka J, Horiike Y, Matsuzaki M, et al. Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science 2008; 319(5870): 1683-1687.
51. Alves-Sampaio A, Troca-Marin JA, Montesinos ML. NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome. J Neurosci 2010; 30(40): 13537-13548.
52. Tongiorgi E. Activity-dependent expression of brain-derived neurotrophic factor in dendrites: facts and open questions. Neurosci Res 2008; 61(4): 335-346.
53. Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci 2000; 3(4): 323-329.
54. Lessmann V, Gottmann K, Heumann R. BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurones. Neuroreport 1994; 6(1): 21-25.
55. Suen PC, Wu K, Levine ES, et al. Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-D-aspartate receptor subunit 1. Proc Natl Acad Sci USA 1997; 94(15): 8191-8195.
56. Jarvis CR, Xiong ZG, Plant JR, et al. Neurotrophin modulation of NMDA receptors in cultured murine and isolated rat neurons. J Neurophysiol 1997; 78(5): 2363-2371.
57. Lin SY, Wu K, Levine ES, et al. BDNF acutely increases tyrosine phosphorylation of the NMDA receptor subunit 2B in cortical and hippocampal postsynaptic densities. Brain Res Mol Brain Res 1998; 55(1): 20-27.
58. Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA 1998; 95(17): 10235-10239.
59. Dogliotti G, Galliera E, Licastro F, Corsi MM. Age-related changes in plasma levels of BDNF in Down syndrome patients. Immun Ageing 2010; 7: 2.
60. Tlili A, Hoischen A, Ripoll C, et al. BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients. Mol Neurobiol 2012; 46(2): 297-303.
61. Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 2010; 4(6): 871-887.
62. Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011; 14(3): 347-353.
63. Siarey RJ, Kline-Burgess A, Cho M, et al. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 2006; 98(4): 1266-1277.
64. Siddiqui A, Lacroix T, Stasko MR, et al. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav 2008; 7(7): 810-820.
65. Bimonte-Nelson HA, Hunter CL, Nelson ME, Granholm AC. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res 2003; 139(1-2): 47-57.
66. Seo H, Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 2005; 193(2): 469-480.
67. Peng S, Garzon DJ, Marchese M, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009; 29(29): 9321-9329.
68. Fukuda Y, Berry TL, Nelson M, et al. Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin. Mol Cell Neurosci 2010; 45(3): 226-233.
69. Bianchi P, Ciani E, Guidi S, et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30(26): 8769-8779.
70. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2011; 221(2): 610-622.
71. Kleschevnikov AM, Belichenko PV, Faizi M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 2012; 32(27): 9217-9227.
72. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33(7): 1624-1632.
73. Altafaj X, Ortiz-Abalia J, Fernandez M, et al. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis 2008; 32(3): 3773-84.
74. Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994; 369(6477): 235-239.
75. Panja D, Dagyte G, Bidinosti M, et al. Novel translational control in Arc-dependent long term potentiation consolidation in vivo. J Biol Chem 2009; 284(46): 31498-31511.
76. Kleschevnikov AM, Belichenko PV, Villar AJ, et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 2004; 24(37): 8153-8160.
77. Costa AC, Grybko MJ. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett 2005; 382(3): 317-322.
78. Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 1997; 36(11-12): 1549-1554.
79. Siarey RJ, Carlson EJ, Epstein CJ, et al. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999; 38(12): 1917-1920.
80. Weston MC, Chen H, Swann JW. Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J Neurosci 2012; 32(33): 11441-11452.
81. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004; 9(4): 359-366.
82. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010; 10(7): 571-581.
83. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10(11): 868-880.
84. Schratt GM, Nigh EA, Chen WG, Hu L, Greenberg ME. BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development. J Neurosci 2004; 24(33): 7366-7377.
85. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105(45): 17414-17419.
86. Chen XG, Liu F, Song XF, et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog 2010; 49(6): 603-610.
87. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol 2011; 164(1): 9-16.